Abstract
Background
Recently, percutaneous transluminal septal myocardial ablation (PTSMA) has been introduced as treatment for symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM).
Methods
We describe our first experience in 24 patients who were treated in our institution during the year 2000.
Results
The procedure was initially successful in all but one patient. In that patient the septal branch that was perfusing the proximal septum could not be found. The procedure was complicated in three patients. One patient died suddenly on the second day after the procedure. Two additional patients needed a permanent pacemaker for persisting total heart block. In the other 22 patients the procedure was successful with an acute decrease of the mean outflow tract gradient from 89±43 mmHg to 21±19 mmHg. In those 19 patients who had a follow-up of at least three months (mean follow-up 172±87 days), the mean NYHA class decreased from 2.7±0.7 before PTSMA to 0.6±0.9 at the last follow-up. The echocardiographic gradient decreased from 92±39 mmHg before the procedure to 26±23 mmHg at the last follow-up.
Conclusions
Our preliminary results demonstrate that PTSMA is an effective treatment for symptomatic patients with HOCM.
Keywords: Hypertrophic obstructive cardiomyopathy (HOCM), percutaneous transluminal septal myocardial ablation (PTSMA)
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Gietzen F. H., Leuner C. J., Raute-Kreinsen U., Dellmann A., Hegselmann J., Strunk-Mueller C., Kuhn H. J. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J. 1999 Sep;20(18):1342–1354. doi: 10.1053/euhj.1999.1520. [DOI] [PubMed] [Google Scholar]
- Kofflard M. J., van Herwerden L. A., Waldstein D. J., Ruygrok P., Boersma E., Taams M. A., Ten Cate F. J. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1996 Jul;28(1):197–202. doi: 10.1016/0735-1097(96)00103-9. [DOI] [PubMed] [Google Scholar]
- Lakkis N. M., Nagueh S. F., Kleiman N. S., Killip D., He Z. X., Verani M. S., Roberts R., Spencer W. H., 3rd Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998 Oct 27;98(17):1750–1755. doi: 10.1161/01.cir.98.17.1750. [DOI] [PubMed] [Google Scholar]
- Maron B. J., Nishimura R. A., Danielson G. K. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation. 1998 Dec 8;98(23):2505–2508. doi: 10.1161/01.cir.98.23.2505. [DOI] [PubMed] [Google Scholar]
- Seggewiss H., Faber L., Ziemssen P. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Cardiol Rev. 1999 Nov-Dec;7(6):316–323. doi: 10.1097/00045415-199911000-00009. [DOI] [PubMed] [Google Scholar]
- Seggewiss H., Gleichmann U., Faber L., Fassbender D., Schmidt H. K., Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol. 1998 Feb;31(2):252–258. doi: 10.1016/s0735-1097(97)00508-1. [DOI] [PubMed] [Google Scholar]
- Spirito P., Seidman C. E., McKenna W. J., Maron B. J. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997 Mar 13;336(11):775–785. doi: 10.1056/NEJM199703133361107. [DOI] [PubMed] [Google Scholar]
- ten Berg J. M., Suttorp M. J., Knaepen P. J., Ernst S. M., Vermeulen F. E., Jaarsma W. Hypertrophic obstructive cardiomyopathy. Initial results and long-term follow-up after Morrow septal myectomy. Circulation. 1994 Oct;90(4):1781–1785. doi: 10.1161/01.cir.90.4.1781. [DOI] [PubMed] [Google Scholar]